Comparative Pharmacology
Head-to-head clinical analysis: K 10 versus K TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 10 versus K TAB.
K+10 vs K-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement; essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
IV: 10 mEq potassium chloride infused at a rate not exceeding 10 mEq/hour via peripheral line; maximum 20 mEq/hour via central line with continuous ECG monitoring. Oral: 20-40 mEq per day in divided doses; maximum 100 mEq per day.
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
None Documented
None Documented
Potassium does not have a true elimination half-life as it is an endogenous ion under homeostatic control. However, intravenously administered potassium has a distribution half-life of approximately 1-1.5 hours and a slow terminal phase reflecting cellular redistribution and eventual excretion. Clinical context: The apparent half-life is highly dependent on renal function and body stores.
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
Potassium is primarily excreted via the kidneys (approximately 90%) with the remainder lost in feces (via colonic secretion). In patients with normal renal function, urinary potassium excretion accounts for >90% of elimination. Fecal excretion is minimal (≤10%) but increases in renal impairment.
Renal (90% unchanged), fecal (10% as metabolites)
Category C
Category C
Potassium Supplement
Potassium Supplement